INSMED Inc
About INSMED Inc
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $606.4M
- Net income
- -$1.3B
- Total assets
- $2.3B
- Market cap
- $20.4B
- Gross margin
- 79.7%
- Operating margin
- -205.6%
- Net margin
- -210.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $606.4M
- Cost of revenue
- $122.9M
- Gross profit
- $483.5M
- Operating expenses
- $1.7B
- Operating income
- -$1.2B
- Income tax
- $5.0M
- Net income
- -$1.3B
- EPS (basic)
- $-6.42
- EPS (diluted)
- $-6.42
Balance sheet
- Total assets
- $2.3B
- Current assets
- $1.8B
- Total liabilities
- $1.5B
- Current liabilities
- $468.9M
- Shareholders’ equity
- $739.0M
Cash flow
- Operating cash flow
- -$935.0M
- Investing cash flow
- -$64.6M
- Financing cash flow
- $954.1M
- Net cash flow
- -$44.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $20.4B
- EPS (diluted)
- $-6.42
- Shares outstanding
- 222.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 1, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.3B in FY2025.
- Revenue grew 222% from FY2021 to FY2025.
- Gross margin of 79.7%, net margin -210.5%.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review INSMED Inc.
Write a review
News about INSMED Inc
News & sentiment via Polygon.io
